AstraZeneca PLC (AZN)vsThe Cooper Companies, Inc (COO)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
COO
The Cooper Companies, Inc
$60.00
-1.82%
HEALTHCARE · Cap: $11.92B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1356% more annual revenue ($60.44B vs $4.15B). AZN leads profitability with a 17.2% profit margin vs 9.7%. AZN appears more attractively valued with a PEG of 1.52. COO earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy62
out of 100
Grade: C+
COO
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+62.5%
Fair Value
$221.31
Current Price
$60.00
$161.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 20.8%
Earnings expanding 26.9% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
ROE of 4.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : COO
The strongest argument for COO centers on Price/Book, Operating Margin, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : COO
The primary concerns for COO are PEG Ratio, P/E Ratio, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while COO is a value play — different risk/reward profiles.
COO carries more volatility with a beta of 0.89 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
COO scores higher overall (63/100 vs 62/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
The Cooper Companies, Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?